Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-κB pathway in macrophages and splenocytes

(2013) Chai Siah Ku et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

1-Arylsulfonyl-5-(N-hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors

(2013) Hsueh-Yun Lee et al.   CHEMBIOCHEM

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment

(2012) Georg Schett et al.   Nature Reviews Rheumatology

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo

(2012) Han-Lin Huang et al.   PLoS One

Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis

(2012) E. Choy   RHEUMATOLOGY

Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay

(2011) Aleksander M Grabiec et al.   ANNALS OF THE RHEUMATIC DISEASES

HDAC3 and HDAC7 Have Opposite Effects on Osteoclast Differentiation

(2011) Lan Pham et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro

(2011) M.D. Cantley et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases

(2011) Melissa D. Cantley et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells

(2011) E. F. de Zoeten et al.   MOLECULAR AND CELLULAR BIOLOGY

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Unknown

(2011) Leo Joosten et al.   MOLECULAR MEDICINE

SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease

(2011) Michal Mielcarek et al.   PLoS One

Histone deacetylases as regulators of inflammation and immunity

(2011) Melanie R. Shakespear et al.   TRENDS IN IMMUNOLOGY

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

(2010) Tomoko Kawabata et al.   ARTHRITIS RESEARCH & THERAPY

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL

(2009) Ha-Neui Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis

(2009) Beatrix Bartok et al.   IMMUNOLOGICAL REVIEWS

Histone Deacetylase Inhibitors: New Hope for Rheumatoid Arthritis?

(2008) Q. Choo et al.   CURRENT PHARMACEUTICAL DESIGN

The aggresome pathway as a target for therapy in hematologic malignancies

(2008) Tiffany Simms-Waldrip et al.   MOLECULAR GENETICS AND METABOLISM

Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model

(2008) Y. Nasu et al.   OSTEOARTHRITIS AND CARTILAGE